口服GnRH拮抗剂TU2670在健康女性中的首次人体双盲随机对照试验
该首次人体、多中心、随机双盲安慰剂对照单剂量递增试验纳入16名健康绝经前女性,在月经开始后7天给予20、40、80、160 mg TU2670或安慰剂。结果显示TU2670耐受良好,药代动力学呈剂量依赖性,并剂量依赖性抑制LH、FSH和雌二醇。
要点
- TU2670单次口服在健康绝经前女性中耐受良好。
- TU2670暴露量(AUClast、Cmax)随剂量增加而增加。
- TU2670剂量依赖性抑制LH、FSH和雌二醇。
核心结论
- 单次给予TU2670在健康绝经前女性中耐受良好,并剂量依赖性抑制LH、FSH和雌二醇,提示快速显著抑制垂体和卵巢激素。
研究设计与样本
- 首次人体、多中心、1期、随机、双盲、安慰剂对照、单剂量递增试验。
- 共16名健康绝经前女性(23至45岁)随机接受20、40、80、160 mg TU2670或安慰剂,于月经开始后7天(±1天)给药。
主要发现
- 生命体征、心电图、不良事件、排卵试验结果和超声检查在各治疗组间无显著差异。
- TU2670中位Tmax为给药后0.75至1.00小时,平均表观半衰期(t1/2)为3.0至5.9小时。
- AUClast(17.7-417.9 ng·h/mL)和Cmax(8.1-95.4 ng/mL)呈剂量依赖性增加。
- 单次给药后PD分析显示LH、FSH和雌二醇呈剂量依赖性抑制。
- LH最大抑制(占给药前基线百分比)为58%至82%(6至8小时),FSH为28%至39%(6至12小时),雌二醇为34%至82%(12至24小时)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TU2670, a novel orally active, nonpeptide gonadotropin-releasing hormone (GnRH) antagonist administered to healthy female participants. METHODS: This was a first-in-human, multicenter, phase 1, randomized, double-blind, placebo-controlled, single-dose ascending trial that took place in multiple medical centers. A total of 16 healthy premenopausal women (23 to 45 years of age) were randomized and received 20, 40, 80, and 160 mg TU2670 (GnRH antagonist) or placebo 7 days (±1 day) after the onset of menstrual bleeding. We performed a noncompartmental analysis for pharmacokinetic parameters and calculated relative minimum concentration values (Cmin, % Baseline) of serum pharmacodynamic (PD) markers (luteinizing hormone [LH], follicle-stimulating hormone [FSH], and estradiol). RESULTS: There were no significant differences among treatments with respect to vital signs, electrocardiography, adverse events, ovulation test results, and ultrasonography. The median Tmax of TU2670 occurred 0.75 to 1.00 hours after dosing, and concentrations then declined, with a mean apparent half-life (t1/2) of 3.0 to 5.9 hours. AUClast (17.7-417.9 ng·h/mL) and Cmax (8.1-95.4 ng/mL) increased in a dose-dependent manner. The PD analysis after a single administration of TU2670 revealed dose-dependent suppression of LH, FSH, and estradiol. Maximal suppression of the pre-dose baseline (%) was 58% to 82% at 6 to 8 hours for LH, 28% to 39% at 6 to 12 hours for FSH, and 34% to 82% at 12 to 24 hours for estradiol. CONCLUSION: The single administration of TU2670 in healthy premenopausal women was well tolerated and resulted in the dose-dependent suppression of LH, FSH, and estradiol, suggesting rapid and significant inhibition of pituitary and ovarian hormones.
引用
- Han S, Cho YS, Yoon SK, et al. First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women. J Clin Endocrinol Metab. 2021. PMID: 33347565. doi:10.1210/clinem/dgaa939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。